Zustovich F - Search Results

1

Advanced kidney cancer: treating the elderly.

Zustovich F, Novara G. Zustovich F, et al. Expert Rev Anticancer Ther. 2013 Dec;13(12):1389-98. doi: 10.1586/14737140.2013.846095. Epub 2013 Nov 14. Expert Rev Anticancer Ther. 2013. PMID: 24224483 Review.

2

A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors.

Zustovich F, Cartei G, Ceravolo R, Zovato S, Della Puppa A, Pastorelli D, Mattiazzi M, Bertorelle R, Gardiman MP. Zustovich F, et al. Anticancer Res. 2007 Mar-Apr;27(2):1019-24. Anticancer Res. 2007. PMID: 17465237 Free article. Clinical Trial.

3

Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.

Pastorelli D, Zustovich F, Faggioni G, Zovato S, Donach M, Nicoletto O, Farina M, Furini L, Ceravolo R, Carli P, Lombardi G. Pastorelli D, et al. Among authors: zustovich f. Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f. Anticancer Drugs. 2010. PMID: 19952729

4

An update on targeted therapy in metastatic renal cell carcinoma.

Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. Lombardi G, et al. Among authors: zustovich f. Urol Oncol. 2012 May-Jun;30(3):240-6. doi: 10.1016/j.urolonc.2009.12.018. Epub 2010 Apr 24. Urol Oncol. 2012. PMID: 20456985 Review.

5

Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.

Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma M, Rotilio A, Nicoletto O, Zagonel V. Zustovich F, et al. Anticancer Res. 2010 Dec;30(12):5213-6. Anticancer Res. 2010. PMID: 21187515

6

Second-line therapy for refractory renal-cell carcinoma.

Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Zustovich F, et al. Crit Rev Oncol Hematol. 2012 Jul;83(1):112-22. doi: 10.1016/j.critrevonc.2011.08.008. Epub 2011 Sep 22. Crit Rev Oncol Hematol. 2012. PMID: 21944739 Review.

7

Treating patients with metastatic renal carcinoma: an escape from Phase III.

Zustovich F, Lombardi G, Farina P. Zustovich F, et al. Expert Rev Anticancer Ther. 2012 Jul;12(7):919-27. doi: 10.1586/era.12.64. Expert Rev Anticancer Ther. 2012. PMID: 22845407 Review.

8

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, Amoroso D, Galli C, Andreuccetti M, Falcone A, Zagonel V. Zustovich F, et al. Anticancer Res. 2013 Aug;33(8):3487-94. Anticancer Res. 2013. PMID: 23898124 Clinical Trial.

9

Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series.

Zustovich F, Ferro A, Lombardi G, Zagonel V, Fiduccia P, Farina P. Zustovich F, et al. Anticancer Res. 2013 Sep;33(9):4061-5. Anticancer Res. 2013. PMID: 24023350

10

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Procopio G, et al. Among authors: zustovich f. Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18. Future Oncol. 2014. PMID: 24641206

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters